HGH vs LL-37
FDA Approved vs Well Studied
synergistic Mechanism-based · 47% HGH and LL-37 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
HGH LL-37
Weight 22,124 Da —
Half-life 3-4 hours (SC), 20-30 minutes (IV) Short (rapid proteolytic degradation)
Chain 191 amino acids 37 amino acids
Type Single-chain polypeptide with two disulfide bridges Cationic antimicrobial peptide
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
LL-37
01 Direct wound healing acceleration
02 Broad-spectrum antimicrobial activity
03 Activity against resistant bacteria (MRSA, MDRPA)
04 Enhanced tissue regeneration
05 Immune modulation
06 Local antimicrobial protection
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
LL-37
0.5-1.6 mg/mL topical gel or 100-150 mcg injectable / Topical: Daily to twice weekly on wounds. Injectable: Once daily subcutaneous
Systemic immune support 100-150mcg Once daily
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
LL-37
Generally well-tolerated
Mild injection site reactions (injectable)
Local irritation at application site (topical)
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Pre-existing hypersensitivity to peptides
Compromised immune status (relative contraindication)
Non-sterile wound environments
Research Evidence
HGH LL-37
Status FDA Approved Well Studied
References 4 studies 4 studies
Latest 2024 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.